RxDoctor Payments Data

Dustin Timmons, APRN

Psychiatric/Mental Health · Jonesboro, ARNPI 1912164229

Payments from drug & device makers

$1,536in general payments, 2019–2025

Across 67 payments — averaging $22.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$403
  • Alkermes, Inc.$236
  • Supernus Pharmaceuticals, Inc.$200
  • Axsome Therapeutics, Inc.$168
  • Teva Pharmaceuticals USA, Inc.$129
  • Otsuka America Pharmaceutical, Inc.$129
  • plus $273 from 8 others

What the payments were for

  • Food & beverage$1,42593%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,536 in reported general payments places this provider in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

See all psychiatric/mental health providers in Arkansas

Medicare billing

Part B allowed, 2024
$7,475
Medicare patients
35
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$148,148
Paliperidone ErPaliperidone20$2,232
Ziprasidone Hcl20$1,777
Buspirone Hcl100$1,411
Hydroxyzine Pamoate17$1,112
Doxepin Hcl42$1,110
Duloxetine Hcl83$987
Quetiapine Fumarate59$914
Aripiprazole58$906
Divalproex Sodium33$691
Trazodone Hcl92$653
Venlafaxine Hcl ErVenlafaxine Hcl50$521
Bupropion XlBupropion Hcl31$456
Hydroxyzine Hcl19$438
Amitriptyline Hcl32$430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$403$148,14818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 359 psychiatric/mental health providers in Arkansas.

Other psychiatric/mental health in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →